Condition: Glucose Intolerance After a Recent History of Gestational Diabetes · Sponsor: Universitaire Ziekenhuizen KU Leuven
Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery. Moreover, women with a history of GDM progress more rapidly to T2DM compared to women with similarly elevated glucose levels. Early intervention after the index pregnancy is therefore crucial to prevent T2DM. With the SERENA project, the investigators aim to reduce the risk to develop T2DM with the long-acting GLP-1 agonist semaglutide in women with a recent history of GDM and glucose intolerance in early postpartum.
This description comes directly from the study's public registry record.
Katrien Benhalima, MD PhD · 16340614 · katrien.benhalima@uzleuven.be
Always discuss trial participation with your own doctor first.
| AZORG | Aalst, Belgium | Recruiting |
| UZA | Antwerp, Belgium | Recruiting |
| ZAS | Antwerp, Belgium | Recruiting |
| AZ St Jan Brugge | Bruges, Belgium | Recruiting |
| Erasme | Brussels, Belgium | Recruiting |
| UZ Brussel | Brussels, Belgium | Recruiting |
| Jan Yperman | Ieper, Belgium | Recruiting |
| AZ Groeninge Kortrijk | Kortrijk, Belgium | Recruiting |
| UZ Leuven | Leuven, Belgium | Recruiting |
| CHU de Liège | Liège, Belgium | Recruiting |
| Centre Hospitalier Mouscron | Mouscron, Belgium | Recruiting |
| Vitaz | Sint-Niklaas, Belgium | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05569772